Triple-negative breast cancer (TNBC) is a poor prognostic breast cancer subtype characterized by the lack of estrogen and progesterone receptors and the amplification of the human epidermal growth factor receptor 2 (HER2) gene, comprises approximately 15%–20% of invasive breast cancers (Garrido-Castro et al., 2019; Giaquinto et al., 2022). This evidence concerns the gene ERBB2 and invasive breast carcinoma.